IMS Reports the Multidisciplinary Approaches to Minimally Invasive Cancer Treatment Using JCI MN Colloidal Iodine

TOKYO--(BUSINESS WIRE)-- Ryusuke Fujiki, Clinical Head and President of Fujiki Hospital, lectured about multidisciplinary approaches which are getting remarkable effect to minimally invasive cancer treatment using JCI MN Colloidal Iodine.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190906005092/en/

Dr. Fujiki (Photo: Business Wire)

On 23 June, 2019, Dr. Fujiki announced in the lecture for approx. 200 medical researcher as follows:

Cancer is not just comprised of cancer cells alone. For this reason, to improve the response rate and treatment efficiency, it is important to view cancer as a conglomerate of “cancer cells” and “all of the interstitial components” that make up a malignant tumor.

Most conventional cancer treatment targets cancer cells which are all genetically diverse and likely to acquire drug resistance. Therefore, these cancers are likely to develop treatment resistance and treatment tolerance so that variations in treatment do not catch up with the diversity of the cancers.

Among the challenges clinicians face is that cancers in patients are completely different from experimental cancers because of the tumor environment in the former. Its importance has drawn much attention in recent years.

Resistance is unlikely to develop against treatments that target the malignant tumor environment and few adverse effects are associated with these treatments. Based on this treatment strategy, he has conducted clinical studies on the evaluation and possibilities of treatment through the use of colloidal iodine through biomodulation in cancer treatment in a multidisciplinary approach that includes low dose chemotherapy, thermotherapy, and hyperbaric oxygen treatment.

The patients who participated in this clinical study were 13 individuals who had been diagnosed with unresectable advanced cancer and were deemed untreatable. He investigated the possibility that the use of JCI MN colloidal iodine used in combination with the 3 modalities of low dose chemotherapy, thermotherapy, and hyperbaric oxygen treatment would work as biomodulation of the malignant tumor environment and contribute to an improved response rate and treatment effectiveness.

Efficacy was assessed based on blood tests, CT, and endoscopic images after 1 month of treatment.

Route of administration for colloidal iodine preparation was selected for each individual patient as oral ingestion, direct application and intravenous infusion.

Fujiki explained as follows.

The van der Waals’ intermolecular force characteristics of iodine are marked.

In particular, it is effective in removing the ROS of mitochondrial origin. The result is recovery of mitochondrial function, changing the anaerobic environment of the tumor environment to an aerobic environment allowing the cells to normalize and recover.

Replacement therapy in ascites involves replacing the acidic ascites with alkaline colloidal iodine solution. This decreases cancer-related fibroblasts (CAF) which are at the leading instigator in creating an intraperitoneal inflammatory environment and helps reduce tumor-facilitating exosome miRNA and inflammatory cytokine production, leading to an improvement in the malignant tumor environment. Add to that the bactericidal efficacy of colloidal iodine and the result is cancer tissue inhibition. This is the direct effect of colloidal iodine.

Colloidal iodine preparation (Iodine + water molecule aggregate) has a higher affinity for Rb and p53 than for Mdm2 or tumor protein so due to the molecular chaperone effect, it binds rapidly and stabilizes after binding to the cancer suppression gene. This inhibits degradation of the cancer suppressor gene by tumor protein.

Thus, colloidal iodine is believed to act as immunotherapy through a different mechanism than immune checkpoint inhibitors. The bactericidal effects of iodine inhibit inflammatory cytokines in the microenvironment of cancer, prevent macrophage migration, mitochondria recover functioning, and the anaerobic metabolism of cancer is inhibited and tumor environment is improved. Improvement of malignant tumor environment helps immune checkpoint inhibitors express their effects.

Discussion of JCI Colloidal Iodine use with chemotherapy

By inhibiting degradation of cancer inhibitory genes by cancer tumor protein, G2-M arrest in the cell cycle and cancer inhibitory gene dependent apoptosis are promoted and potentiates the effects of chemotherapy.

Furthermore, it forms a conjugate with inflammatory cytokines and the tumor proteins that break off and are fragmented by chemotherapy, inactivating the proteins and cytokines and attenuating multi-drug resistance to chemotherapy.

Conclusion

Colloidal iodine is a new type of immunotherapy that has a completely different mechanism of action than checkpoint inhibitors. Biogenetical modulation regulates the formation of the gene-cancer protein complex, inhibits activation of the cancer gene and prevents decreased functioning of the cancer inhibiting gene. It thus allows recovery of immune function homeostasis and shows marked improvement of response rates and treatment efficacy when used concomitantly with thermotherapy and hyperbaric oxygen therapy.

Compared to immune checkpoint inhibitors, hardly any adverse drug reactions occur. It is a treatment that has a biochemical modulation (BCM) effect on chemotherapy and thus may overcome multidrug resistance to chemotherapy. In a broad sense, colloidal iodine has a biomodulating effect and contributes to improving the effectiveness of cancer treatment.

The cases we presented today were almost all high advanced cancers in Stage 4 or candidates for palliative care. The fact that we were able to achieve rapid and marked improvement of clinical condition in barely a month with no adverse effects allows us to recognize the importance of targeting the tumor environment in cancer for treatment. We believe our findings will have a major impact on the future direction of cancer treatment.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190906005092/en/